Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-9813 in Pulmonary Fibrosis
NCT07192939Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-9813 in idiopathic pulmonary fibrosis (IPF), pulmonary fibrosis (PF), sponsored by Hengrui Therapeutics. Started Oct 2025; status: recruiting.
02
Drugs
HRS-9813
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT07192939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07192939.